Echinococcosis: An Economic Evaluation of a Veterinary Public Health Intervention in Rural Canada

Janna M. Schurer1*, Ellen Rafferty2*, Marwa Farag2‡, Wu Zeng3, Emily J. Jenkins1‡

1 Department of Veterinary Microbiology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada, 2 School of Public Health, University of Saskatchewan, Saskatoon, Saskatchewan, Canada, 3 Schneider Institutes for Health Policy, Heller School, Brandeis University, Waltham, Massachusetts, United States of America

* These authors contributed equally to this work.
‡ These authors were co-principal investigators on this work.
* jschurer@gmail.com

Abstract

Echinococcosis is a rare but endemic condition in people in Canada, caused by a zoonotic cestode for which the source of human infection is ingestion of parasite eggs shed by canids. The objectives of this study were to identify risk factors associated with infection and to measure the cost-utility of introducing an echinococcosis prevention program in a rural area. We analyzed human case reports submitted to the Canadian Institutes for Health Information between 2002 and 2011. Over this 10 year period, there were 48 cases associated with E. granulosus/E. canadensis, 16 with E. multilocularis, and 251 cases of echinococcosis for which species was not identified (total 315 cases). Nationally, annual incidence of echinococcosis was 0.14 cases per 100,000 people, which is likely an underestimate due to under-diagnosis and under-reporting. Risk factors for echinococcosis included female gender, age (>65 years), and residing in one of the northern territories (Nunavut, Yukon, or Northwest Territories). The average cost of treating a case of cystic echinococcosis in Canada was $8,842 CAD. Cost-utility analysis revealed that dosing dogs with praziquantel (a cestocide) at six week intervals to control cystic echinococcosis is not currently cost-effective at a threshold of $20,000-100,000 per Quality Adjusted Life Year (QALY) gained, even in a health region with the highest incidence rate in Canada ($666,978 -755,051 per QALY gained). However, threshold analysis demonstrated that the program may become cost-saving at an echinococcosis incidence of 13-85 cases per 100,000 people and therefore, even one additional CE case in a community of 9000 people could result in the monetary benefits of the program outweighing costs.

Author Summary

In Canada, Echinococcus spp. tapeworms cycle primarily among wildlife hosts. People are infected with this parasite when they accidentally consume microscopic eggs spread by...
canids (e.g. dogs, wolves, coyotes, and foxes), and develop larval cysts, often in the liver or lungs. Echinococcosis can be a life-threatening medical condition with long-term health consequences and can be an economic burden for infected individuals and for the public health system. We analysed national health records to measure echinococcosis incidence and risk factors in Canada, and then used this information to determine if a program that facilitated dog deworming to prevent human infection might be economically feasible. Our model suggested that treating infected individuals is currently less expensive than preventing infection, even in the highest risk regions of Canada. However, deworming dogs might be feasible in small rural communities where at least one case was identified. Furthermore, the prevention program has many add-on benefits that contribute to overall community health, but are not measured by our model.

Introduction

Echinococcosis, also known as hydatid disease, is a potentially fatal condition caused by zoonotic cestodes of the genus *Echinococcus* [1]. Two species are endemic to Canada: *E. multilocularis*, which causes alveolar echinococcosis (AE), and *E. canadensis* (formerly known as the G8 and G10 genotypes, or the cervid/sylvatic strains of *E. granulosus*), which causes cystic echinococcosis (CE) [1–3]. Human cases of echinococcosis are considered rare, resulting in approximately 0.72 hospitalizations per million people per year [4]. Domestically-acquired cases are thought to be almost exclusively CE (caused by *E. canadensis*), and appear to occur more commonly in northern latitudes (>55°), in women, and in groups of Indigenous descent [2,4–6]. Foreign-acquired cases of echinococcosis could be caused by other species not present in Canada (e.g. *E. granulosus sensu strictu*), and may be associated with more severe disease. Echinococcosis is under-diagnosed in people due to an often prolonged disease progression, asymptomatic or nonspecific symptoms, and the difficulty of definitive diagnosis—especially in northern areas where medical imaging services are limited [1,7,8]. It is also under-reported, as there is no formal requirement to report human cases to national public health authorities in Canada. Recent studies highlight the need to better determine the incidence and health care burden associated with human echinococcosis in Canada, especially in rural, remote, and Indigenous communities [4,9,10].

The life cycle of *E. canadensis* is indirect, and utilizes wild cervids such as moose (*Alces alces*), elk (*Cervus canadensis*), and caribou (*Rangifer tarandus*) as intermediate hosts. Canids such as wolves (*Canis lupus*), coyotes (*C. latrans*), and dogs (*C. familiaris*) serve as definitive hosts [11–13]. Neither intermediate hosts nor definitive hosts are thought to suffer serious adverse effects as a result of infection; however, intermediate hosts may be at higher risk of predation due to decreased pulmonary function [14,15]. In Canada, *E. multilocularis* utilizes canid definitive hosts (e.g. coyotes, wolves, foxes [*Vulpes* spp.], and dogs) and rodents (arvicoline and neotamine) as normal intermediate hosts [2]. In contrast to *E. canadensis*, intermediate hosts of *E. multilocularis* experience more severe adverse effects [16]. People become infected by accidentally ingesting eggs shed by definitive hosts. Dogs have been identified as high risk reservoirs for human exposure to both species of *Echinococcus*, especially in areas where dogs can access offal or scavenge rodents as a food source, and where poverty is prevalent [1,17,18].

Worldwide, echinococcosis affects 2–3 million people per year, at an estimated cost of $750 million USD [19]. In countries where livestock strains of *E. granulosus* are highly prevalent, this disease represents a significant economic burden to healthcare systems, as well as to animal production systems [1,20,21]. For all forms of echinococcosis, there is the possibility for
recurrence and of long-term sequelae following treatment, further increasing the burden of disease [1,22]. Multiple countries have implemented programs with various strategies to control and/or eliminate CE [1]. The most effective strategy is generally believed to be treatment of dogs with praziquantel (PZQ), a cestocide effective against *Echinococcus* spp., at six week intervals in concert with surveillance of people, dogs and livestock (1). Dog population reduction can also factor into these programs. Few studies have calculated the cost effectiveness of CE prevention programs and none have been done in Canada where the status quo is simply to treat infected people [23–25]. The goals of this paper are to 1) report the incidence of echinococcosis based on existing national datasets, and 2) determine the cost-utility of using a CE prevention strategy (6-week PZQ dog dosing) in comparison to status quo, for a high risk health region in Canada using both public pay and societal perspectives.

**Methods**

**Database**

We obtained case records for Canadians diagnosed with echinococcosis from the Discharge Abstract Database (DAD) and National Ambulatory Care Reporting System (NACRS) for 2002–2011 through the Canadian Institute for Health Information (CIHI). Nationally, DAD captures all acute hospital inpatient cases, including deaths, discharges and hospital transfers; while NACRS collects ambulatory cases through voluntary submissions from day surgery, outpatient clinics and emergency department visits. Cases were coded using version 10 of the International Classification of Diseases (ICD-10) coding system of the World Health Organization. DAD did not report data from one province (Quebec -QC) unless a resident was treated out of province, but did report data from all other provinces and territories (BC—British Columbia, AB—Alberta, SK—Saskatchewan, MB—Manitoba, ON—Ontario, NL—Newfoundland and Labrador, NS—Nova Scotia, NB—New Brunswick, YT—Yukon Territories, NT—Northwest Territories, NU—Nunavut). Other omissions included MB and NB data for 2002/2003 and NB data for 2003/2004 due to delays in transitioning from ICD-9 to ICD-10 coding. NACRS abstract submissions were biased towards ON, as this was the only province with mandated reporting during the study period. Due to the small population in the 3 northern territories (YT, NT, NU), these cases were grouped together to avoid identifying patients or communities. Our dataset did differentiate between international patients and citizens, but did not report travel history or whether a person had recently immigrated to Canada. Cost and length of stay estimates were only available for 2009/2010 and 2010/2011.

Anonymized patient records from the NACRS and DAD databases were analyzed using SPSS statistical software (version 20; Chicago, Illinois, USA). Individual health card identification numbers (issued by provinces and territories to individuals enabling free access to insured health care services) were assigned a Meaningless But Unique Number (MBUN), which we used to ensure that each individual was counted only once over the study period. Treatment costs and length of stay estimates of individuals hospitalized multiple times were combined for that individual. Rural/urban and neighbourhood quintile income classifications were based on an individual’s postal code, and geographic location was reported by health region (according to a patient’s health card). Rural/urban residence categories adhered to Statistics Canada definitions: (1) Rural (outside or fringe of Census Metropolitan Areas (CMAs) or Census Agglomerations (CAs)); (2) Urban Core (large urban area with ≥50 000 people for CMA or ≥10 000 people for CA); (3) Urban Fringe (small urban areas inside CMA or CA but separated from the urban core); (4) Urban areas outside CMAs/CAs (small towns with a population of 1000–10000 people and population density of ≥400 persons/km²) [26]. Other variables included age (categorized as <14, 15–64 and >65 years), gender, province where treatment occurred, and
discharge status (i.e. a patient’s health status or anticipated location after leaving the hospital). Population proportions of infection were compared for risk factors using the Z-test, with statistical significance reported at the P < 0.05 level. Only individuals over 14 years of age were included in the rural/urban comparison because the comparison dataset provided by Statistics Canada is limited to this age group. Incidence was reported as the median rate over 10 years [27].

Economic Evaluation

For this evaluation, we focused on CE caused by *E. canadensis*, which is thought to be the primary species endemically transmitted in Canada [2]. We conducted a cost-utility analysis comparing a strategy for CE prevention, PZQ dog dosing, with the status quo (no prevention). Cost-utility analysis presents the cost per Quality Adjusted Life Year (QALY) and therefore captures the costs associated with CE, along with its impact on quantity and quality of life. We modelled one cohort, representing the health region with the highest incidence rate (Kelsey Trail, SK) and included residents of all ages, over the lifetime of the patient, to fully represent the long-term consequences of the disease and the possibility for recurrence. Consistent with the Canadian Agency for Drugs and Technologies in Health (CADTH) guidelines, we used a public payer perspective to represent all the public sector costs associated with CE and the PZQ dog dosing program, and thereby characterised the interests of both the prevention program and the health care system funders. Furthermore, we presented the societal perspective to represent the indirect costs, such as loss of productivity and travel expenses. We considered a cost per QALY between $20,000–100,000 as cost-effective, < $20,000 as very cost-effective and ≤ $0 per QALY gained as cost-saving as per [28].

PZQ Dog Dosing Program Description

The Kelsey Trail Health Region is home to 42,218 people (2013–2014 estimate), of which approximately half reside in population centres with veterinary services [29]. These centres also have animal control by-laws that prohibit dogs from running freely, require all owners to register their dogs annually, and impose fines on animal owners who do not remove animal waste from public areas. The PZQ dog dosing program considered in this paper included re-homing unwanted dogs from rural/remote communities, as per [30], as well as the following:

1. CE Surveillance: People and dogs monitored to identify high priority communities
2. PZQ dosing at 6 week intervals:
   a. Population centres with dog bylaws and veterinary clinics—dog owners given PZQ tablets free of charge at annual registration
   b. Rural/remote communities with no animal bylaws or veterinary clinics—program veterinarian injects dogs with PZQ 2–8 times annually depending on logistical constraints (e.g. accessibility, road conditions) and canine echinococcosis prevalence
3. Education: Echinococcosis teaching materials provided to primary and secondary school teachers

Modelling

We used decision analysis to construct a Markov cohort simulation model within Treeage to determine incremental cost-utility. The model ran for 79 years or the average life expectancy of a resident of the Kelsey Trail Health Region [31], with Markov cycles occurring at one year iterations. For both the PZQ program and status quo, the model considered the transition between
five CE health states (Healthy, Sick, Sequelae, Fully Recovered, Dead), each with associated costs and utilities. Transition probabilities determined the likelihood of moving between states.

**Data Inputs**

Three types of costs were considered: CE treatment costs, CE indirect costs, and PZQ prevention program costs (S1 Appendix). We estimated the average treatment costs per CE case using estimates provided by CIHI and adding physician costs. Physician costs were estimated based on the Saskatchewan Ministry of Health Payment Schedule for Insured Services Provided by a Physician and expert physician opinion. PZQ program costs included a veterinarian salary [32], vehicle use for travel in and between communities, and the wholesale costs of PZQ. Finally, indirect costs included loss of production due to treatment (one month lost earnings), loss of production due to mortality (average income lost from death until life expectancy), and travel costs (car travel and hotel) [33]. All costs were provided in 2011 Canadian dollars.

We used utilities, which quantify the health wellbeing of an individual, to value the outcomes observed in each health state, with dead having a utility of zero and the healthy average Canadian having a utility of 0.93. Utility scores are weights representing preferences for different health states. The more preferred health states receive higher weights. Utilities are measured on a scale of 0–1, where 0 indicates death and 1 indicates perfect health [34]. Utility scores/weights for different health states could be obtained using Quality of Life instruments [35] and the Standard Gamble approach [36]. The sickness utility represents both the time when an individual is sick and when they were undergoing treatment. Our CE sickness utility (0.72) was based on estimates for hepatic resection and liver cancer, as these illnesses have similar treatments and outcomes [37,38]. Post treatment, those who fully recovered were assumed to return to the healthy state utility of 0.93, whereas those with sequelae had a slightly lower utility of 0.89. The sequelae utility was based on a SF-36 quality of life study of echinococcosis patients who had already undergone treatment but still experience effects of the disease [20,39].

We calculated the risk of developing CE in Kelsey Trail Health Region using the incidence of hospitalization from the CIHI databases (AE cases were excluded; Table 1). The course of disease and the likelihood of different outcomes, including the risk of recurrent echinococcosis, risk of sequelae, fatality rates and all-cause mortality rates were derived from the literature [1,22,40–42]. Costs and utilities were both discounted at a rate of 5% as recommended in the CADTH guidelines, with sensitivity analysis at 0% and 3% discount levels [43].

We calculated the baseline relative risk (RR) of acquiring CE using a PZQ dosing strategy versus status quo from CE incidence estimates in Chile before and after the implementation of a similar PZQ program [22]. In the regions where the Chilean PZQ program was applied, the CE incidence in people decreased from ~60 per 100,000 to 11.8 per 100,000 within 10 years (a RR = 0.19) [22]. Therefore, to represent changes in CE risk following PZQ dosing while taking into account the time-lag between PZQ treatment and impact on human health, we used a table function that decreased the RR every year, from 0.919 the first year, until it reached the base rate of RR = 0.19 after 10 years. For the rest of the model the RR was held constant at 0.19 to represent the possibility that the program missed some infected dogs. We chose the Chilean prevention program and the associated RR as the base estimate for our study because it targeted a similar pathogen (*E. granulosus* sensu strictu) to that observed in Canada, as well as being one of few programs conducted on a continent rather than an island.

To ensure the validity of the model and the robustness of the findings, we conducted one-way sensitivity analyses of key variables, including risk of echinococcosis, dog-to-human ratio, fatality rate and discount rate. Plausible ranges were derived from 95% confidence intervals, inter-quartile ranges or the literature. Finally, a threshold analysis was conducted to determine
the level at which PZQ dosing would be cost-saving, and to identify the minimum incidence rate that would result in a cost-effectiveness of \(<\ 20,000\) per QALY (Quality Adjusted Life Year).

**Ethics**

This project was reviewed and approved by the University of Saskatchewan Biomedical Ethics Review Board (REB protocol number 13–51), which adheres to national standards set out by the Tri-Council for research involving humans. We report data at the level of the public health region (or pooled for the sparsely-populated northern territories) to avoid inadvertently identifying individual patients or communities.

**Results**

**Statistical Analysis**

Between 2002 and 2011, 384 discharge abstracts were submitted to the DAD and NACRS databases for patients under-going treatment for echinococcosis. Of these, 69 abstracts were removed from descriptive analyses either because they were duplicates (the same individual obtaining medical care on multiple occasions), or because they lacked sufficient information to be assigned an MBUN. The median annual incidence rate was 0.14 cases per 100 000 people (range: \(0.12 \text{–} 0.25\) cases per 100 000). The median age of echinococcosis cases was 46 years. The highest frequency of cases was observed in females, those aged \(15 \text{–} 64\), those residing in an urban core, and those residing in neighbourhoods with the lowest income quintile ranking (Table 2). Relative to the 2006 Census estimates of female: male ratios [46], the proportion of female cases was significantly higher than the proportion of male cases at the national level and in three provinces (BC- 13:6, \(P = 0.012\); AB- 25:6, \(P = 0.032\), ON- 18:11, \(P = 0.001\)). The proportion of cases in the top age category (\(<\ 65\) years) was significantly higher than the other two categories at the national level, and in AB, ON, and MB (\(P = 0.001\), \(P<0.001\), and \(P = 0.01\), respectively). In BC the proportion of cases in the top age category was significantly higher than the proportion of cases in the youngest age category (\(P = 0.02\)), but not the middle age group.

---

**Table 1. Summary of base estimates and plausible ranges for utility and probability model inputs for cystic echinococcosis treatment and prevention in Canada.**

| Utility Variable                  | Base Estimate | Plausible Ranges          | References |
|-----------------------------------|---------------|---------------------------|------------|
| Healthy                           | 0.93          | 1–0.86                    | [44]       |
| Sickness                          | 0.72          | 0.58–0.86                 | [37,38]    |
| Sequelae                          | 0.89          | 0.8–0.93                  | [20]       |
| Dead                              | 0             | 0                         | N/A        |
| Cystic Echinococcosis Risk        | 0.000017      | 0.00000707–0.000033        | DAD/NACRS  |
| Relative Risk                     | 0.19 (after 10yrs)\(^1\) | 0.4–0.05                  | [22]       |
| Recurrence                        | 0.16          | 0.05–0.27                 | [1]        |
| Sequelae                          | 0.075         | 0.02–0.15                 | [41,45]    |
| Fatality Rate                     | 0.03          | 0.01–0.05                 | [22,40,41] |
| All-Cause Mortality              | 0.0057        | 0.0056–0.0059             | [42]       |
| Discount Rate (Costs & Effects)   | 0.05          | 0 & 0.03                  | [43]       |

\(^1\)Relative Risk (RR) was calculated for each year from the start of the prevention program using a table function that decreased the RR of getting echinococcosis by 8% each year until it reached the base RR of 0.19 after 10 years.

doi:10.1371/journal.pntd.0003883.t001
We observed no significant difference in urban versus rural incidence among patients older than 14 years. The highest proportion of cases were observed in the territories (NU, NT, YK), while the lowest were observed in Atlantic Canada (NL, NS, PE, and NB). The proportion of cases in these provinces and territories were all significantly different from the proportion of cases in ON (the most populous province in Canada). Our data suggests that the majority of echinococcosis patients were treated within their province of residence (311/323, 96%), except for those residing in the territories who were all treated out of territory (NL, MB, or AB).

Table 2. Description of patients receiving care for echinococcosis in Canada (2002–2011).

| Descriptor                        | Frequency | % of cases¹ | Proportion of Population x 10⁶ | P-value |
|-----------------------------------|-----------|-------------|-------------------------------|---------|
| Gender                            |           |             |                               |         |
| Female                            | 209       | 66.3        | 13                            | <0.001  |
| Male                              | 106       | 33.7        | 7                             |         |
| Age (years)                       |           |             |                               |         |
| 0–14                              | 22        | 7.0         | 4                             | <0.001  |
| 15–64                             | 207       | 65.7        | 5                             | <0.001  |
| ≥65                               | 86        | 27.3        | 20                            |         |
| Urban/Rural²                      |           |             |                               |         |
| Rural                             | 29        | 11.2        | 9                             | 0.27    |
| Urban core                        | 208       | 80.3        | 11                            | Reference|
| Urban fringe                      | 5         | 1.9         | 5                             | 0.11    |
| Urban area outside CMA/CA         | 17        | 6.6         | 10                            | 0.65    |
| Missing                           | 56        | -           | -                             |         |
| Neighbourhood Income Quintile³    |           |             |                               |         |
| 1- $14 800                        | 91        | 29.3        | -                             |         |
| 2 - $25 800                       | 65        | 20.9        | -                             |         |
| 3 - $35 300                       | 59        | 19.0        | -                             |         |
| 4 - $46 900                       | 50        | 16.1        | -                             |         |
| 5 - $78 800                       | 46        | 14.8        | -                             |         |
| Missing                           | 4         | -           | -                             |         |
| Province⁴                         |           |             |                               |         |
| British Columbia                  | 38        | 12.1        | 9                             | 0.10    |
| Alberta                           | 51        | 16.2        | 15                            | 0.72    |
| Saskatchewan                      | 17        | 5.4         | 18                            | 0.48    |
| Manitoba                          | 17        | 5.4         | 15                            | 0.97    |
| Ontario                           | 178       | 56.5        | 15                            | Reference|
| Quebec⁵                           | 1         | 0.3         | -                             | -       |
| Newfoundland & Labrador           | 2         | 0.6         | 4                             | 0.04    |
| Nova Scotia                       | 3         | 1.0         | 3                             | <0.01   |
| New Brunswick                     | 2         | 0.6         | 3                             | <0.01   |
| Yukon, Northwest Territories & Nunavut | 6       | 1.9         | 59                            | <0.001  |

¹Percent of cases where descriptor data is available
²Only cases aged >14 years used in rural/urban analysis; CMA—Census Metropolitan Area, CA—Census Agglomeration
³Average adjusted after-tax income for individuals calculated for 2006 in 2009 constant dollars (http://www.statcan.gc.ca/pub/75-202-x/2009000/analysis-analyses-eng.htm#a2)
⁴According to patient health card
⁵Only Quebec residents who received medical care out of province were captured in this analysis

doi:10.1371/journal.pntd.0003883.t002
Annual incidence rates were highest in the Kelsey Trail Health region (1.7 cases/100,000) in SK and the Norman Regional Health Authority (1.2 cases/100,000) in MB (Fig 1).

Abstracts in this dataset reported cyst location within the body in 60% of cases (188/315), and the species of *Echinococcus* in 20% of cases (64/315; Table 3). For CE, the most commonly reported cyst location was lung, followed by liver, multiple sites, and bone; whereas liver and multiples sites were the most common descriptors for AE. Of the 305 cases that described discharge disposition, 2.3% ended in fatality.

**Economic Evaluation**

We based our model on the Kelsey Trail Health Region (SK), which had the highest CE incidence rate in Canada (1.7 cases/100,000). The average cost to treat a single CE case was $8,841.68. The prevention program has a significant yearly cost, approximately $654,033, due to high numbers of dogs in rural areas and high drug costs (S1 Appendix). Furthermore the analysis showed a very small utility gain from using a prevention program compared to status quo (Incr. QALY = +0.00031870). All these factors resulted in a very high incremental cost-utility ratio (ICUR) for the base public pay case ($755,051 per QALY gained). Moreover, the societal perspective did not drastically change the outcome, with a cost per QALY gained of $666,978 (Table 4).

One-way sensitivity analysis demonstrated that none of the cost-utility ratios for any of the plausible variable ranges were under $100,000 per QALY. The best cost-utility ratio came at the high range of the plausible risk of CE (0.0000316 or incidence of 3.16 per 100,000) using the societal perspective with a cost per QALY of approximately $311,143. Varying other data inputs did not significantly change the outcomes, most likely because the starting incidence was so low, thereby making other probabilities irrelevant. Sensitivity of the analysis to the risk of developing CE prompted us to conduct a threshold analysis to determine at what incidence the prevention program might be considered cost-effective. This analysis found that an incidence between 10–37 cases per 100,000 the cost per QALY would be approximately $20,000, while an incidence of 13–85 per 100,000 (risk = 0.000014) would result in the program becoming cost-saving (Table 5).

**Discussion**

We report an echinococcosis incidence rate of 0.14 cases per 100,000 annually, which is slightly higher than a previous Canadian estimate, likely because we included cases where echinococcosis was not the primary diagnosis. This is lower than CE incidence rates in other endemic countries including Spain, Portugal, Italy, Greece, and China; but is higher than New Zealand or the island of Tasmania which are provisionally free following the success of control programs [1,22]. We believe that our incidence rate under-estimates the true incidence because CE is not nationally notifiable to public health authorities in Canada, cases were removed from analysis due to incomplete identifier data, the dataset does not include all emergency room discharges or private clinics, and because up to 60% of CE cases (especially those caused by the sylvatic form in Canada) are thought to be asymptomatic [1]. Furthermore, over 150 cases of unspecified liver disease were reported annually during the study time period, suggesting that under-diagnosis of echinococcosis may occur [47]. Based on the best data currently available, we were not able to determine what proportion of cases were foreign-acquired; however, the universal nature of health care in Canada means that costs of treatment of foreign-acquired cases are still incurred.

Although the majority of case reports did not differentiate between CE and AE, highlighting another weakness in reporting, our findings suggest that most CE cases were likely to be
domestically-acquired. The geographic distribution of CE cases (Fig 1) is very similar to the known range of *E. canadensis* in cervids and wolves in Canada (prevalent in the north, absent in the Atlantic provinces) [2, 12, 13], further supporting that these cases are likely endemically acquired. The highest incidence rates were in northern areas of SK, MB and the territories(YK, NU and NT) as opposed to health regions where large metropolises are present (Fig 1). All of the top primary, secondary and tertiary immigration destinations in English-speaking Canada (Toronto, Vancouver, Calgary, Edmonton, Winnipeg, Hamilton, Ottawa, Saskatoon, Victoria, etc.)
Regina, and Halifax) had very low incidence rates [48]. This emphasizes the need for veterinary public health efforts and improved awareness of *Echinococcus* transmission in northwestern Canada. Sixteen individuals were diagnosed with AE over the ten year study period, which could be explained by *E. multilocularis* emergence or incorrect use of ICD codes by physicians. In Canada, AE cases are generally thought to be foreign-acquired, as no autochthonous cases have been reported in Canada since 1928 [49]. However, six of these individuals resided in northern health regions of BC, AB, ON, and in the northern territories (YK, NU, NT), where immigration rates are presumably low. *Echinococcus multilocularis* is has been observed in wildlife in BC, AB, SK, MB, NT, and NU, and European strains of this tapeworm were recently detected in a domestic dog (as AE) and in wild canids (as adult cestodes) [13,47,50,51]. European strains may have greater zoonotic potential than strains of the parasite long established in the southern parts of the western Canadian provinces (AB, SK, and MB), and this may be supported by the recent emergence of AE in dogs in Canada [49, 50, 52], which is more typically seen in regions of Europe highly endemic for *E. multilocularis*. Heightened surveillance for AE is warranted, as it generally results in worse health outcomes and significantly higher treatment costs than for CE [53].

Our findings that echinococcosis diagnosis occurred more commonly in females and older adults are comparable with other Canadian studies [4,6]. Cases of CE were most likely to have pulmonary or hepatic involvement, which is a common finding for the cervid strains in people. These findings of gender, age and tissue predilection site are risk factors shared by wildlife

| ICD-10 code | Species | Cyst location | Frequency | % of cases |
|------------|---------|---------------|-----------|------------|
| B67.0      | *E. granulosus*¹ | Liver         | 16        | 5.1        |
| B67.1      | *E. granulosus*¹ | Lung          | 21        | 6.7        |
| B67.2      | *E. granulosus*¹ | Bone          | 2         | 0.6        |
| B67.3      | *E. granulosus*¹ | Multiple sites| 8         | 2.5        |
| B67.4      | *E. granulosus*¹ | Unspecified site | 1 | 0.3        |
| B67.5      | *E. multilocularis* | Liver         | 8         | 2.5        |
| B67.6      | *E. multilocularis* | Multiple sites| 6         | 1.9        |
| B67.7      | *E. multilocularis* | Unspecified site | 2 | 0.6        |
| B67.8      | Echinococcus² | Liver         | 141       | 44.8       |
| B67.9      | Echinococcus² | Unspecified site | 110 | 34.9       |

¹ Presumably *E. canadensis* under new taxonomy, if domestically-acquired
²Species unspecified

doi:10.1371/journal.pntd.0003883.t003

| Payment Perspective | Average Costs per Person ($) | Average QALY per Person | Incremental Cost-Utility ratio (ICUR) |
|---------------------|----------------------------|-------------------------|--------------------------------------|
| Public Pay          |                            |                         |                                      |
| Status quo          | 8.13                       | 17.3070                 |                                      |
| Prevention (PZQ)    | 248.76                     | 17.3073                 |                                      |
| Incremental         | +240.63                    | +0.0003187              | $755,051 per QALY gained             |
| Societal            |                            |                         |                                      |
| Status Quo          | 58.63                      | 17.3070                 |                                      |
| Prevention (PZQ)    | 271.20                     | 17.3073                 |                                      |
| Incremental         | +212.56                    | +0.00031870             | $666,978 per QALY gained             |

doi:10.1371/journal.pntd.0003883.t004

Table 3. Cyst location and *Echinococcus* species in Canadian echinococcosis cases (2002–2011).

Table 4. Base case incremental cost per QALY and total costs (Can$).
cervid hosts for *E. canadensis* [6,12,54]. The highest frequency of CE cases occurred in low income neighborhoods but we were unable to determine if the proportion of cases relative to other income quintiles was significantly different. Low income individuals might be at higher risk of CE if they fed raw offal to pets and were unable to afford regular cestocidal dosing for dogs.

We report a CE treatment cost that is similar to that in the UK ($10,215 USD), but far higher than that in other countries such as Jordan ($524 USD) [41]. At an ICUR of $755,051 per QALY gained, the dog dosing prevention program was not cost-effective relative to other funded health care programs and current willingness-to-pay guidelines [28]. The current incidence and drug costs, including indirect (societal) costs, yields an ICUR of $666,978 per QALY gained, which is also not cost-effective. To date, few CE/AE prevention programs have been evaluated from an economic perspective [53]. This is a major gap in the literature as these programs may be very cost-effective in higher incidence countries. In fact, although PZQ dosing is not currently cost-effective at the health region level, it may be cost-effective at a smaller community level. The average population per community in Kelsey Trail Health Region is 660 people; therefore, even one CE case per year in a community could warrant a prevention strategy in that community, especially if the source of CE is linked back to the dog population, rather than directly from wildlife. According to the threshold analysis, even one CE case in a community of 9000 people a year could be potentially cost saving for society. Furthermore, as CE incidence increases, the cost-effectiveness of a prevention program becomes more and more dependent on the indirect costs, especially productivity loss. A similar PZQ dog dosing program, delivered concurrently with sheep and goat vaccination, was thought to be cost-effective or even cost saving in Shiqu County (China), where the incidence of human CE (caused by *E. granulosus* livestock strains) and AE is extremely high [55]. Therefore, it is important that other CE/AE endemic countries engage in evaluations to determine the cost-effectiveness of echinococcosis prevention programs using domestic estimates for incidence, cost, and targeting the strains endemic in their region.

Important considerations exist that might further impact the cost-utility and feasibility of the PZQ dosing program. First, veterinarians use PZQ to treat dogs against a wide range of cestode species in addition to *E. canadensis*, including *Diphyllobothrium* spp., *Taenia* spp., *Dipylidium caninum*, and *Mesocestoides* spp., some of which can infect people and/or livestock. Other treatments to prevent zoonotic diseases in dogs, such as nematocides or rabies vaccination, could easily be added to the PZQ program infrastructure at a lower cost than administering all treatments separately. Second, the World Health Organization suggests that the control

### Table 5. Threshold and sensitivity analyses for the societal perspective.

| Variable                      | Cost per QALY (Can$) |
|-------------------------------|----------------------|
| **Risk of Disease- Societal** |                      |
| Low (0.00000707)              | 1,748,684            |
| High (0.0000316)              | 311,143              |
| Threshold (0.0001)            | 20,000               |
| Threshold (0.00013)           | 0                    |
| **Risk of Disease- Public Pay** |                     |
| Low (0.00000707)              | 1,836,755            |
| High (0.0000316)              | 399,220              |
| Threshold (0.00037)           | 20,000               |
| Threshold (0.00085)           | 0                    |

doi:10.1371/journal.pntd.0003883.t005
of echinococcosis go through multiple phases: 1) planning; 2) attack (costly and intensive control measures implemented); 3) consolidation (only high risk animals and people targeted); and 4) maintenance [1]. While the complete eradication of echinococcosis in Canada is not feasible due to wildlife reservoir hosts, there remains the possibility of future cost reductions of the prevention program. For example, after echinococcosis rates in people and animals decreased, this low risk status could be maintained through cheaper methods (e.g. education, owner-administered PZQ, screening high risk dogs). Third, our threshold analysis demonstrated that an increased incidence of echinococcosis could markedly impact the cost-utility of a prevention program. Fourth, this program would target under-served and vulnerable populations that have poorer health outcomes, and therefore, the benefit of preventing disease in these risk groups may help to reduce health inequalities. Lastly, our results indicated that all YK, NU and NT patients travelled out of territory for treatment, which can be very expensive for the health care system, as this generally involves travel by air. In NU, more than 25% of the operations budget is spent sending patients to southern referral centres to obtain care that is unavailable in the north, which drastically increases the costs of treating CE and demonstrates the benefits of a prevention program [56].

Conclusions

Our study provides baseline human echinococcosis data that is otherwise unavailable for Canada, since there is no national reporting or targeted surveillance. Improvements to echinococcosis surveillance could include development of serological tests that are optimal for Canadian strains (e.g. *E. canadensis* G8 and G10), improved classification of echinococcosis by physicians (i.e. to species and/or genotype level, which can help determine pathogenicity and if cases are endemically or foreign acquired), increased awareness of echinococcosis among physicians in areas where this parasite is prevalent, and addition of this parasite to the list of nationally notifiable pathogens. Improving surveillance would allow policy-makers and governments to make informed decisions about implementing control programs, with the knowledge that increasing incidence greatly improves the cost-utility of an echinococcosis prevention program. Although PZQ dosing did not appear to be cost effective under current conditions at the level of the health region in Canada, it might still be warranted in high risk communities, especially as there are added benefits to people, pets and wildlife in controlling *Echinococcus* and other zoonotic cestodes.

Supporting Information

S1 Appendix. Summary of data inputs, base estimates, and sensitivity analyses for cystic echinococcosis control in Canada. (DOCX)

Acknowledgments

The authors thank Dr. Fiona Clement and Dr. Braden Manns for their advice and help in developing the economic model.

Author Contributions

Conceived and designed the experiments: JMS ER MF. Performed the experiments: JMS ER WZ. Analyzed the data: JMS ER WZ. Contributed reagents/materials/analysis tools: ER EJJ. Wrote the paper: JMS ER WZ MF EJJ.
References

1. Eckert J, Gemmell M, Meslin F-X, Pawlowski Z. WHO/OIE Manual of echinococcosis in humans and animals: a public health problem of global concern. Organization for Animal Health and World Health Organization; 2001.

2. Jenkins E, Castrodale L, de Rosemond S, Dixon B, Elmore S, Gesy K, et al. Tradition and transition: Parasitic zoonoses in people and animals in northern North American and Greenland. Adv Parasitol. 2013; 82:33–204. doi:10.1016/B978-0-12-407706-5.00002-2 PMID:23549088

3. Nakao M, Lavikainen A, Yanagida T, Ito A. Phylogenetic systematics of the genus Echinococcus (Cestoda: Taeniidae). Int J Parasitol. 2013; 43:1017–29. doi:10.1016/j.ijpara.2013.06.002 PMID:23872521

4. Gilbert N, Oluwayemisi K, Libman M, Muchaal P, Ogden N. Hospitalization for trichinellosis and echinococcosis in Canada, 2001–2005: The tip of the iceberg? Can J Public Health. 2010; 101:337–40. PMID:21033550

5. Lamy A, Cameron B, LeBlanc J, Culham G, Blair G, Taylor G. Giant hydatid lung cysts in the Canadian Northwest: Outcome of conservative treatment in three children. J Pediatr Surg. 1993; 28:1140–3. PMID:8308679

6. Somily A, Robinson J, Miedzinski L, Bhargava R, Marrie T. Echinococcal disease in Alberta, Canada: more than a calcified opacity. BMC Infect Dis. 2013; 5:e319. doi:10.1371/journal.pntd.0000319 PMID:23872521

7. Bristow B, Lee S, Shafir S, Sorvillo F. Human echinococcosis mortality in the United States, 1990–2007. PLOS Negl Trop Dis. 2012; 6:e1524. doi:10.1371/journal.pntd.0001524 PMID:22347516

8. Torgerson P, Dowling P. Estimating the economic effects of cystic echinococcosis. Part 2: an endemic region in the United Kingdom, a wealthy, industrialized economy. Ann Trop Med Parasitol. 2001; 95:77–85. PMID:11299124

9. Bristow B, Lee S, Shafir S, Sorvillo F. Human echinococcosis mortality in the United States, 1990–2007. PLOS Negl Trop Dis. 2012; 6:e1524. doi:10.1371/journal.pntd.0001524 PMID:22347516

10. Torgerson P. Economic effects of echinococcosis. Acta Trop. 2003; 85:113–8. PMID:12606088

11. Attanasio E, Palmas C. Cost-effectiveness analysis of echinococcosis hydatidosis eradication project in Sardinia. Soc Sci Med. 1984; 19:1067–72. PMID:6441260

12. Battelli G. Echinococcosis: costs, losses and social consequences of a neglected zoonosis. Vet Res Commun. 2009; 33:S47–52.
25. Wang L, Wen H, Feng X, Jiang X, Duan X. Analysis of economic burden for patients with cystic echinococcosis in five hospital in northwest China. Trans Roy Soc Trop Med Hyg. 2012; 106:743–8. doi:10.1016/j.trstmh.2012.09.003 PMID: 23122883

26. Statistics Canada. Urban core, urban fringe and rural fringe [Internet]. 2009 [cited 2014 Jun 21]. https://www12.statcan.gc.ca/census-recensement/2006/ref/dict/geo050a-eng.cfm

27. Statistics Canada. Annual estimates of population for Canada, provinces and territories, from July 1, 1971 to July 1, 2014 [Internet]. 2014. http://www.stats.gov.nl.ca/statistics/population/PDF/Annual_Pop_Prov.PDF

28. Laupaciš A, Feeny D, Detsky A, Tugwell P. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J. 1992; 146:473–81.

29. Harper R. Kelsey Trail Health Region annual report to the Minister of Health [Internet]. Kelsey Trail Health Region; 2013 [cited 2014 Oct 9]. http://www.kelseytrailhealth.ca/Publications/AnnualReport/Documents/2013-14%20Annual%20Report.pdf

30. Schurer J, Phipps K, Okemow C, Beatch H, Jenkins E. Stabilizing dog populations and improving animal and public health through a participatory approach in Indigenous communities. Zoonoses Public Health. 2014.

31. Kelsey Trail Health Region annual report 2009–2010 [Internet]. 2010 [cited 2015 Feb 11]. http://www.kelseytrailhealth.ca/Publications/AnnualReport/Documents/2009-10%20Annual%20Report.pdf

32. Veterinary salary (Canada) [Internet]. PayScale. 2015 [cited 2015 Feb 12]. http://www.payscale.com/research/CA/Job=Veterinarian/Salary

33. Statistics Canada. Individuals by total income level, by province and territory (Saskatchewan) [Internet]. 2014 [cited 2015 Jan 10]. http://www.statcan.gc.ca/tvfr/tabs-tableaux/sum-som10/cst01/fami105i-eng.htm

34. Whitehead SJ, Ali S. Health outcomes in economic evaluation: the QALY and utilities. Brit Med Bull. 2010; 96:5–21. doi:10.1093/bmb/ldq033 PMID: 21037243

35. Wee HL, Machin D, Loke WC, Cheung YB, Luo N et al. Assessing differences in utility scores: A comparison of four widely used preference-based instruments. Value Health, 2007; 10:256–265. PMID: 17645680

36. Gafni A. The Gamble method: What is being measured and how it is interpreted. Health Serv Res. 2004; 29:207–224.

37. McLernon D, Dillon J, Donnan P. Health-state utilities in liver disease: A systematic review. Med Decis Making. 2008; 28:582–92. doi: 10.1177/0272989X08315240 PMID: 18424560

38. Cucchetti A, Piscaglia F, Cescon M, Colecchia A, Ercolani G, Bolondi L, et al. Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma. J Hepatol. 2013; 59:300–7. doi: 10.1016/j.jhep.2013.04.009 PMID: 23603669

39. Fryback D, Lawrence W, Martins P, Klein R, Klein B. Predicting quality of well-being scores from the SF-36: Results from the beaver dam health outcomes study. Med Decis Making. 1997; 17:1–29. PMID: 8994146

40. WHO Informal Working Group on Echinococcosis. Guidelines for treatment of cystic and alveolar echinococcosis in humans. Bull Wld Hlth Org. 1996; 74:231–42.

41. Carabin H, Budke C, Cowan L, Wellinham Ill A, Torgerson P. Methods for assessing the burden of parasitic zoonoses: echinococcosis and cysticercosis. Trends in Parasitology. 2005; 21:327–33. PMID: 15922667

42. Saskatchewan Health. Mortality [Internet]. 2013 [cited 2014 Sep 16]. http://www.health.gov.sk.ca/hsr/chapter5-mortality-sept-2013

43. CADTH. Guidelines for the economic evaluation of health technologies: Canada. 3rd Edition. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2006.

44. Mittman N, Traka K, Risebrough N, Liu B. Utility scores for chronic conditions in a community-dwelling population. Pharmacoeconomics. 1999; 15:369–76. PMID: 10537955

45. Majorowski M, Carabin H, Kilani M, Bensalah. Echinococcosis in Tunisia: a cost analysis. Trans Roy Soc Trop Med Hyg. 2005; 99:268–78. PMID: 15708386

46. Statistics Canada. 2006 Census of population [Internet]. 2014 [cited 2014 Jun 17]. https://www12.statcan.gc.ca/census-recensement/2006/index-eng.cfm

47. Massolo A, Licioll S, Budke C, Klein C. Echinococcus multilocularis in North America: the great unknown. Parasite. 2014; 21:73. doi: 10.1051/parasite/2014069 PMID: 25531581

48. Government of Canada. Recent immigrants in metropolitan areas: Canada—A comparative profile based on the 2001 census [Internet]. Citizenship and Immigration Canada. 2005 [cited 2014 Jul 7]. http://www.cic.gc.ca/english/resources/research/census2001/canada/partg.asp
49. James E, Boyd W. *Echinococcus alveolaris* (with report of a case). Can Med Assoc J. 1937; 36(4):354–6. PMID: 20320583

50. Jenkins E, Hill J, Somers C, Gesy K, Bames B. Detection of European strain *Echinococcus multilocularis* in North America. Emerg Infect Dis. 2012; 18:1010–2. doi: 10.3201/eid1806.111420 PMID: 22608114

51. Gesy K, Hill JE, Schwantje H, Liccioli S, Jenkins EJ. Establishment of a European-type strain of *Echinococcus multilocularis* in Canadian wildlife. Parasitol. 2013; 140:1133–1137.

52. Skelding A, Brooks A, Stalker M, Mercer N, de Villa E, Gottstein B, et al. Hepatic alveolar hydatid disease (*Echinococcus multilocularis*) in a boxer dog from southern Ontario. Can Vet J. 2014; 55:551–3. PMID: 24891637

53. Heggin D, Deplazes P. Control of *Echinococcus multilocularis*: Strategies, feasibility and cost-benefit analyses. Int J Parasitol. 2013; 43:327–37. doi: 10.1016/j.ijpara.2012.11.013 PMID: 23384814

54. Moro P, Schantz P. Echinococcosis: a review. Int J Infect Dis. 2009; 13:125–33. doi: 10.1016/j.ijid.2008.03.037 PMID: 18938096

55. Budke C, Jiamin Q, Qian W, Torgerson P. Economic effects of echinococcosis in a disease-endemic region of the Tibetan Plateau. Am J Trop Med Hyg. 2005; 73:2–10. PMID: 16014823

56. Government of Nunavut, Department of Health and Social Services. 2011/2012 Annual report on the operation of the medical care plan [Internet]. 2012 [cited 2014 Oct 23]. http://assembly.nu.ca/library/GNEdocs/2012/000851-e.pdf